Open Access Article
Ling-Yang
Wang
a,
Yue-Ming
Yu
a,
Ming-Chao
Yu
a,
Yan-Tuan
Li
*ab,
Zhi-Yong
Wu
a and
Cui-Wei
Yan
*a
aSchool of Medicine and Pharmacy and College of Marine Life Science, Ocean University of China, Qingdao, Shandong 266003, PR China. E-mail: yantuanli@ouc.edu.cn
bLaboratory for Marine Drugs and Bioproducts, Qingdao National Laboratory for Marine Science, Qingdao, Shandong, PR China
First published on 13th June 2023
Correction for ‘A crystalline solid adduct of sulfathiazole–amantadine: the first dual-drug molecular salt containing both antiviral and antibacterial ingredients’ by Ling-Yang Wang et al., CrystEngComm, 2020, 22, 3804–3813, https://doi.org/10.1039/D0CE00368A.
This CrystEngComm paper reports the formation of a molecular salt of amantadine–sulfathiazole prepared via a salification strategy, whereas ref. 1 reports the formation of an amantadine hydrochloride–sulfathiazole co-crystal through a cocrystallization strategy. Therefore, although both papers report different cocrystallization and salification strategies, ref. 1 should have been cited in this CrystEngComm article.
There is also an error in the caption of Fig. 5. The correct caption is shown below.
Fig. 5 XRPD comparisons of (a) ATD, (b) SFZ, and the (c) experimental and (d) simulated patterns of SFZ-ATD.
In addition, the FTIR spectrum of amantadine (ATD) presented in Fig. S1(a) was incorrect. The correct FTIR spectrum is provided in the revised supporting information with the original article.
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
| This journal is © The Royal Society of Chemistry 2023 |